He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.
They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.
They are an interesting company, spun out of the PHM-X group. They have been executing very well. There was a study that looked at what happens when people are closely monitored and it was very in favour in terms of what Biomed does. This is home monitoring of the COPD disease so they can push them out of hospitals sooner. They were growing at 20% per year organically. He continues to own it. PHM-X also looks really attractive now.
They're the number three player in U.S. respiratory providers. They were spun out of Patient Home Monitoring. 30% ROE. As long as they execute and grow organically, their stock price will rise in 1-2 years. (no dividend, Anaylsts' price target: $9.75)
Provides breathing masks and other respiratory support services. He expects significant growth and sees it as reasonably priced relative to projected earnings.
Viemed Healthcare is a Canadian stock, trading under the symbol VMD-T on the Toronto Stock Exchange (VMD-CT). It is usually referred to as TSX:VMD or VMD-T
In the last year, 3 stock analysts published opinions about VMD-T. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Viemed Healthcare.
Viemed Healthcare was recommended as a Top Pick by Peter Hodson on 2020-11-17. Read the latest stock experts ratings for Viemed Healthcare.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Viemed Healthcare In the last year. It is a trending stock that is worth watching.
On 2021-01-21, Viemed Healthcare (VMD-T) stock closed at a price of $10.87.
He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.